Back to School: How biopharma can reboot drug development. Access exclusive analysis here
The U.K.'s NICE amended a decision on the use of Lucentis ranibizumab from Novartis (NVS; SWX:NOVN) for wet age-related macular degeneration (AMD) to
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury